Print

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT05572684 (https://clinicaltrials.gov/show/NCT05572684)

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

Study Contact Information:

For additional information, please contact:

Associate Director Clinical Operations at NextCure Inc. by phone (859)468-8632 or email NCClin@nextcure.com

Director of Clinical Research  by phone (240)399-4900 or email NelsonM@nextcure.com

 

About the Study

This study will test the safety and effectiveness of a new immunotherapy drug called NC410 used in combination with the immunotherapy agent Keytruda (pembrolizumab) in people with advanced or metastatic cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:

What the Study Involves

All participants will receive the study drug NC410 injected by IV every 2 weeks and Keytruda injected IV every 6 weeks until the treatment stops working or causes serious side effects.

Study Sites

Arizona

Colorado

Kentucky

Maryland

New Jersey

Ohio

Texas

Virginia

Washington

This Study is Open To:

Patients 18 years or older who have advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal, head and neck, lung or cervical cancer, and:

This Study is Not Open To:

Patients who:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.